Analysed ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) News Sources
FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
09-10-2026
yahoo.com
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
09-10-2026
yahoo.com
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
10-10-2026
yahoo.com
What is the current price of ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS)?
The current price of ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) is $54.09.
ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) absolute price change since previous trading day?
The absolute price change of ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) since the previous trading day is $0.72.
ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) percentage price change since previous trading day?
The percentage price change of ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) since the previous trading day is 1.3491%.
What is the most recent average sentiment score for ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS)?
The most recent average sentiment score for ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) is 71 out of 100.
What is the most recent average sentiment for ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS)?
The most recent sentiment for ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS) is .
SEC-8K** Filing Available For ROCHE HOLDINGS LTD-SPONS ADR (RHHBY:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.